All amounts in USD
Scientific Program Registration Fees
- Advances in Urologic Care : $695 per physician
- This rate only applies to individuals who wish to receive an attendance certificate
- Accommodation must be booked through Cameleo CME
The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Harvard Medical School designates this live activity for a maximum of 19.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advances in Urologic Care is a three-day, comprehensive course covering the diagnosis and management of benign and malignant urologic conditions. Recent advances in the surgical and medical management of urologic conditions will be reviewed during case-based lectures deliv- ered by faculty with expertise in their respective fields.
Over the course of three days participants will also be able to enjoy didactic lectures given by Harvard Faculty, plenary sessions given by Keynote speakers, and also interactive sessions including clinical management debates and multidisciplinary tumor boards. Material covered in lectures will help participants learn how to optimize the evaluation and care of urologic patients by leveraging emerging technological advancements and evidence based data driven guidelines.
During this course participants will review of both fundamental management principles and also recent updates in the field of urology. The combination of interactive sessions and case based formats will allow participants to obtain practical knowledge to improve their ability to care for patients while also learning about innovations and emerging treatments.
Upon completion of this activity, participants will be able to:
- Accurately diagnose commonly encountered urologic malignancies, including prostate cancer, kidney cancer and bladder cancer.
- Review the risks and benefits of management options for commonly encountered urolog- ic malignancies, including prostate cancer, kidney cancer and bladder cancer.
- Evaluate emerging diagnostic tools, novel therapeutic options and guideline based surveillance regiments, for commonly encountered urologic malignancies, including prostate cancer, kidney cancer and bladder cancer.
- Describe the diagnosis and management of commonly encountered benign urologic conditions.
- Summarize recent updates and innovations in the diagnosis and management of benign urologic conditions.
- Compare emerging diagnostic tools, novel therapeutic options and guideline-based sur- veillance regiments for benign urologic conditions.
Upon reservation, a deposit of $500 will be charged to your credit card. The balance will be payable by credit card on August 19, 2022. You can cancel your reservation at no charge any time before August 18, 2022.